Sanofi ups the ante in vaccines—big-time—with new €350M plant

Sanofi Pasteur's sales growth has outpaced the company's pharma business. (Sanofi on Flickr)

Sanofi CEO Olivier Brandicourt took a hard look at the French drugmaker's operations after he took the helm—and he put its vaccines business front and center in the company's growth plans.

Nothing confirms that decision more obviously than what Sanofi rolled out Thursday: plans for a brand-new €350 million vaccine plant in Canada, one of the company's largest-ever investments in a single facility.

With plans to open in 2021, Sanofi will build the new plant at the Sanofi Pasteur Canadian headquarters in Toronto. The plant will produce five-component acellular pertussis antigens, plus antigens for diphtheria and tetanus vaccines.

Webinar This Week

OTC Innovation to Avoid Stagnation: Survey Insights, Expert Advice, and Latest Technologies to Boost Your Product’s Performance

Join us for a complimentary webinar on November 13 at 11am ET / 8am PT. Listen to industry experts as they analyze the critical role of innovation in OTC products, and strategies for achieving it.

Philippe Luscan, executive vice president of global industrial affairs at Sanofi, said in a statement that the project is "one of the most important investments for the Sanofi global industrial network." 

“It demonstrates our continued commitment to manufacturing excellence and to better serving our vaccines portfolio to people all over the world," he added. David Loew, head of Sanofi's vaccine division, commented that the plant "will take us one step closer to a world where no one suffers or dies from a vaccine-preventable disease.” 

A Sanofi spokesperson said the project will create 2,500 jobs for supply chain vendors and contractors between 2016 and 2021. The company will train internally to fill positions and hire for the plant, she added. 

RELATED: Sanofi Pasteur posts 8.3% growth despite 2017 vaccine setbacks 

Even as some areas of Sanofi's business continue to struggle on stepped-up competition and pricing pressure, Sanofi Pasteur has been a reliable performer. Despite its troubled Dengvaxia launch, the division turned in 8.3% growth in 2017 to €5.1 billion.

Polio, pertussus and Hib vaccines—several of which would be supplied by the new plant—played a big role, growing sales 15.3% to €1.8 billion. Flu vaccine sales grew 8.2% for the year to €1.59 billion, while travel and other endemic-disease vaccines chipped in €493 million, a 19% increase. 

For Dengvaxia, it was another story. The dengue vaccine generated just €3 million in sales and became the subject of a controversy in the Philippines. In November, Sanofi warned of an increased risk of severe dengue in recipients who haven't had prior exposure to the virus, setting off a firestorm.

RELATED: Sanofi creates vaccine growth in 2016 despite lifeless Dengvaxia launch 

Philippine officials quickly stopped a mass vaccination program and asked for a refund. Sanofi ended up refunding €19 million in unused doses and took an inventory impairment charge of €87 million. 

Still, Sanofi's impressive vaccine sales growth for the year compared to an 8% decline for pharma and a 15.2% increase for specialty unit Genzyme. The drugmaker's important diabetes sales slipped 14.3%.  

Last year's vaccines performance also followed a strong year in 2016, when Sanofi Pasteur grew sales by 8.8%, again outpacing pharmaceuticals.

Suggested Articles

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.

Both IL-17A inhibitors have rolled out data showing they work in non-radiographic axial spondyloarthritis.